Introduction {#s1}
============

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and is predicted to become the second leading cause of cancer-specific death by 2030 ([@B1]). Surgery followed by adjuvant chemotherapy has been widely established as the best mean to obtain longer survival. However, this combination therapy can only be applied to 20% of patients, whereas most patients suffered from locally advanced or metastatic diseases, owing to the lack of early clinical symptoms and effective screening methods. Moreover, even after curative resection, up to 80% of patients suffered from recurrence soon after surgery ([@B2]--[@B4]), and the 5-year survival rate was \<6% ([@B5]).

Progression had a truly negative effect on prognoses of patients with PDAC. However, the variations of biological behaviors and clinicopathological factors of tumors would contribute to different patterns and timing of progression even when diseases were classified as the same stages. Although multiple studies illustrated the risk factors of progression, such as resection margin status and lymph node (LN) metastasis ([@B6], [@B7]), the relationship between the prognosis and progression was rarely evaluated for patients with PDAC. The prognosis might be changing among patients with different patterns and timing of progression, whereas significant heterogeneity existed among the current reports regarding patterns and timing of recurrence owing to the small sample sizes and limited period of follow-up ([@B8], [@B9]). Understanding both the risk factors and the patterns of progression of PDAC patients can provide an insight into optimization of the treatment, as well as the surveillance strategies. Although recurrence was associated with decreased survival, whether the sites and timing of recurrence had different influences on survival remained controversial. Thus, the aim of this study was to evaluate the risk factors for different patterns of recurrences and compare the survival differences in PDAC patients with varied patterns or timing of disease progression.

Materials and Methods {#s2}
=====================

Patients
--------

This study included consecutive patients with PDAC who underwent surgical resection at Sun Yat-sen University Cancer Center (SYSUCC) between 2008 and 2018. Excluded patients were those with metastatic diseases detected at diagnosis by radiological examination, such as computed tomography (CT) and magnetic resonance imaging (MRI). Positron emission tomography/CT (PET/CT) and diagnostic laparoscopy were also selectively performed to detect metastases on the basis of the recommendation of the pancreatic multidisciplinary team. The resection margin for radical margin was defined as 1.5--2 mm, which was the same as that of previous studies ([@B10], [@B11]). Excluded were also patients with microscopic or macroscopic incomplete resection, a history of secondary tumors, period of follow-up \<1 year, and missing follow-up records.

Data Collection
---------------

Resectability was judged on the basis of CT or MRI, and staging was determined by the pathological factors in accordance with the 8th edition of American Joint Committee on Cancer staging system ([@B12], [@B13]). A team specialized in pancreatic surgery performed all radical pancreatic resection. An experienced pancreatic pathologist assessed all the surgical specimens, made the diagnosis of PDAC, and described the pathological variables, including tumor site, tumor size, tumor differentiation, T-stage, LN status (N-stage), LN total number, positive LN number, macrovascular invasion, microvascular invasion, lymph vessel invasion, perineural invasion, adjacent organ invasion, and satellite foci. LN ratio (LNR) was defined as the number of LNs with metastases divided by the total number of excised LNs. Several radiological variables, including imaging tumor size, LN metastasis, vascular invasion, and LN size, were analyzed. Inflammation-based indexes, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), prognostic index (PI), and systemic immune-inflammation index (SII), were included in this study and calculated according to previous studies ([@B14], [@B15]). Clinical data were also analyzed in this study, including age, gender, white blood cell (WBC) count, C-reactive protein (CRP), albumin (ALB), serum levels of carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA).

Follow-Up and Recurrence
------------------------

The follow-up of patients occurred at the outpatient clinic of our hospital. In general, follow-up strategies consisted of regular chest CT, abdominal CT, and CA19-9 test at least every 2 months during the first year after surgical resection and every 3 months thereafter. Occasional additional imaging modalities, such as MRI and PET/CT, were selectively performed to determine patterns of recurrence. Follow-up data were retrieved at the end of May 2019. The categories of regression patterns in the study conducted by Groot et al. ([@B4]) were adopted in this study. When considering patterns of recurrence, only the first location of recurrence was documented, and local recurrence and distant recurrence were registered, separately. In addition, distant recurrences were judged as "liver-only" and "lung-only" recurrences for the isolated hepatic and pulmonic recurrence, respectively, and "others" for isolated recurrence in other less common locations. If both local recurrence and isolated distant metastasis occurred or multiple distant metastases were detected at the same time, recurrences were defined as "local + distant" and "multiple" recurrences, respectively.

Survival Outcomes and Statistical Analysis
------------------------------------------

Progression-free survival (PFS) and overall survival (OS) were defined as the duration from the date of surgery until the date when tumor progression was diagnosed and death, respectively, or last follow-up. Post-progression survival (PPS) was defined as the time from the first recurrence to either death or last follow-up. Survival time was estimated using the Kaplan--Meier method, and the subgroup differences were compared with log-rank test. Univariate analyses were performed to describe the association between clinical, pathological, and radiological factors and specific patterns of recurrence. For PFS and OS prediction, multivariate logistic regression was conducted on the basis of clinical characteristics and pathological or radiological variables selected by least absolute shrinkage and selection operator (LASSO) logistic regression model. The prediction algorithms were further validated using receiver operating characteristic (ROC) curves. Area under the ROC curve (AUC) and concordance index (C-index) of the multi-marker algorithms were calculated and compared. Two-tailed *P* \< 0.05 were considered statistically significant. All statistical analyses were conducted using R software version 3.2.5 (R Development Core Team; <http://www.r-project.org>).

Results {#s3}
=======

Patient Characteristic
----------------------

From 2008 to 2018, a total of 355 patients underwent radical pancreaticoduodenectomy (PD) or distal pancreatectomy for histologically confirmed PDAC. Excluded from this cohort were 10 patients with microscopic or macroscopic incomplete resection, 12 patients with second primary tumors, and 31 patients with incomplete follow-up information. Consequently, 302 patients were included into this study. All patients were followed up at least 1 year. At the end of follow-up, 195 patients (64.6%) were alive after a median follow-up of 24.7 months (95% confidence interval \[CI\] 20.3--29.1) from surgery. Recurrence was documented in 173 patients (57.3%), whereas 129 patients (42.7%) had no signs of recurrence. The median follow-up time for patients with and without tumor progression was 13.8 and 40.6 months, respectively.

Timing of Recurrence
--------------------

Among 173 patients who had recurrence, 18 patients had done so within 6 months, 26 within 6--12 months, 57 within 12--24 months, and 72 beyond 24 months after surgery. There were no significant differences in ages and sexes among patients in different recurrent time groups. Primary tumors in early recurrence groups were larger, more likely to be poorly differentiated, and diagnosed at more advanced local stages. Patients with early recurrence had more often T4 tumors, more metastatic LNs, and more often para-aortic LNs (LN16) metastasis than had those in late recurrence groups ([Table 1](#T1){ref-type="table"}). Median PFS was 11.8 months (95% CI 10.2--15.3) for the whole cohort and 7.0 months (95% CI 6.2--8.4) for those who developed recurrences. For patients who developed recurrences, the comparisons of PPS and OS stratified by different time intervals of recurrences are shown in [Figure 1](#F1){ref-type="fig"}. It was shown that median OS and PPS for patients who developed recurrences beyond 24 months over surgery (OS, 45.1 months, 95% CI 40.2--52.6; PPS, 17.1 months, 95% CI 11.1--17.5) were significantly longer than for those who had recurrence within 24 months since surgery. Also, patients had similar OS and PPS when their recurrences developed within 6, 6 to 12, or 12 to 24 months since surgery.

###### 

Clinicopathological characteristics of patients with PDAC stratified by time of metastases.

  **Characteristics**            **Diagnosis of progression**   **Characteristics**   **Diagnosis of progression**                                                                                                             
  ------------------------------ ------------------------------ --------------------- ------------------------------ ---- ---- ---- ---- --------- --------------------------- --------------- ----- ----- ---- ---- ---- ---- -------
  Whole cohort                                                  302                   129                            18   26   57   72             Whole cohort                                302   129   18   26   57   72   
  Age                            ≤60 years                      164                   74                             8    12   29   41   0.670     Perineural invasion         Absence         146   70    8    13   21   34   0.287
                                 \>60 years                     138                   55                             10   14   28   31                                         Presence        156   59    10   13   36   38   
  Gender                         Female                         119                   53                             7    13   25   21   0.286     Adjacent organ invasion     Absence         270   119   15   24   52   60   0.284
                                 Male                           183                   76                             11   13   32   51                                         Presence        32    10    3    2    5    12   
  Recurrence                     Absence                        174                   129                            10   11   11   13   \<0.001   LNR                         0               173   83    12   17   26   35   0.038
                                 Presence                       128                   0                              8    15   46   59                                         0--0.16         66    26    1    7    17   15   
  Recurrence patterns            Absence                        174                   129                            10   11   11   13   \<0.001                               \>0.16          63    20    5    2    14   22   
                                 Local                          39                    0                              4    6    18   11             Satellite foci              Absence         287   123   18   26   55   65   0.197
                                 Liver only                     49                    0                              1    5    14   29                                         Presence        15    6     0    0    2    7    
                                 Lung only                      12                    0                              2    0    4    6              T stage                     T1              82    46    5    9    8    14   0.023
                                 Other sites                    5                     0                              1    3    1    0                                          T2              136   57    8    10   34   27   
                                 Local + distant                14                    0                              0    1    5    8                                          T3              57    18    3    4    12   20   
                                 Multiple                       9                     0                              0    0    4    5                                          T4              27    8     2    3    3    11   
  LN metastasis                  Absence                        174                   83                             13   17   26   35   0.035     Tumor site                  Head            247   111   13   23   46   54   0.221
                                 Presence                       128                   46                             5    9    31   37                                         Body and tail   55    18    5    3    11   18   
  LN5 metastasis                 Absence                        300                   127                            18   26   57   72   0.609     TNM stage                   IA              54    33    4    7    3    7    0.003
                                 Presence                       2                     2                              0    0    0    0                                          IB              74    36    6    7    13   12   
  LN6 metastasis                 Absence                        298                   126                            18   26   57   71   0.672                                 IIA             35    11    2    2    10   10   
                                 Presence                       4                     3                              0    0    0    1                                          IIB             79    32    3    6    21   17   
  LN7 metastasis                 Absence                        296                   128                            17   25   56   70   0.582     Imaging tumor size (cm)     III             60    17    3    4    10   26   
                                 Presence                       6                     1                              1    1    1    2                                          ≤2              104   63    6    5    13   17   0.001
  LN8 metastasis                 Absence                        294                   126                            17   25   57   69   0.561                                 2--4            141   45    9    19   31   37   
                                 Presence                       8                     13                             1    1    0    3                                          \>4             57    21    3    2    13   18   
  LN9 metastasis                 Absence                        292                   125                            17   25   57   68   0.492     Imaging LN metastasis       Absence         175   73    12   15   34   41   0.944
                                 Presence                       10                    4                              1    1    0    4                                          Presence        127   56    6    11   23   31   
  LN10 metastasis                Absence                        295                   127                            17   26   56   69   0.566     Imaging vascular invasion   Absence         234   106   16   22   42   48   0.060
                                 Presence                       7                     2                              1    0    1    3                                          Presence        68    23    2    4    15   24   
  LN11 metastasis                Absence                        294                   126                            18   26   56   68   0.436     Imaging LN size (cm)        ≤0.5            177   72    13   16   35   41   0.884
                                 Presence                       8                     3                              0    0    1    4                                          0.5--1          64    30    1    5    11   17   
  LN12 metastasis                Absence                        268                   116                            18   23   49   62   0.493     PI                          \>1             61    27    4    5    11   14   
                                 Presence                       34                    13                             0    3    8    10                                         0               199   93    12   16   36   42   0.168
  LN13 metastasis                Absence                        231                   103                            15   21   40   52   0.473                                 1               84    31    6    7    19   21   
                                 Presence                       71                    26                             3    5    17   20                                         2               19    5     0    3    2    9    
  LN14 metastasis                Absence                        281                   122                            16   26   52   65   0.402     NLR                         ≤3.32           197   89    13   16   36   43   0.659
                                 Presence                       21                    7                              2    0    5    7                                          \>3.32          105   40    5    10   21   29   
  LN15 metastasis                Absence                        294                   127                            18   26   56   67   0.129     dNLR                        ≤3.32           100   39    10   9    20   22   0.296
                                 Presence                       8                     2                              0    0    1    5                                          \>3.32          202   90    8    17   37   50   
  LN16 metastasis                Absence                        284                   127                            18   26   52   61   0.001     PLR                         ≤98.13          36    17    5    1    7    6    0.135
                                 Presence                       18                    2                              0    0    5    11                                         \>98.13         266   112   13   25   50   66   
  LN17 metastasis                Absence                        293                   124                            18   26   54   71   0.498     PNI                         0               65    31    6    2    11   15   0.277
                                 Presence                       9                     5                              0    0    3    1                                          1               237   98    21   24   46   57   
  LN18 metastasis                Absence                        296                   126                            18   26   54   72   0.234     SII                         ≤1,000          206   90    14   16   26   50   0.706
                                 Presence                       6                     3                              0    0    3    0                                          \>1,000         96    39    4    10   21   22   
  Positive LN number             0                              173                   83                             12   17   26   35   0.046     mGPS                        0               202   93    12   16   38   43   0.677
                                 1--3                           95                    36                             5    8    24   22                                         1               67    23    4    7    11   22   
                                 \>3                            34                    10                             1    1    7    15                                         2               33    13    2    3    8    7    
  Pancreatic membrane invasion   Absence                        184                   81                             15   13   36   39   0.147     WBC count                   ≤10             280   124   18   23   53   62   0.061
                                 Presence                       118                   48                             3    13   21   33                                         \>10            22    5     0    3    4    10   
  Tumor size (cm)                ≤2                             88                    48                             6    10   9    15   0.012     ALB (g/L)                   ≤35             46    19    2    4    12   9    0.704
                                 2--4                           146                   60                             8    10   36   32                                         \>35            256   110   16   22   45   63   
                                 \>4                            68                    21                             4    6    12   25             CRP (ng/L)                  ≤3              202   93    12   16   38   43   0.465
  Tumor differentiation          Well                           2                     0                              0    0    1    1    0.035                                 \>3             100   36    6    10   19   29   
                                 Moderate                       153                   72                             14   12   30   25             CA19-9 (U/ml)               ≤35             59    34    4    5    5    11   0.063
                                 Poor                           147                   57                             4    14   26   46                                         \>35            243   95    14   21   52   61   
  Macrovascular invasion         Absence                        273                   120                            16   23   54   60   0.161     CEA (ng/ml)                 ≤5              205   97    14   17   37   40   0.054
                                 Presence                       29                    9                              2    3    3    12                                         \>5             97    32    4    9    20   32   
  Microvascular invasion         Absence                        206                   87                             15   19   40   45   0.493     HBV infection               Absence         283   120   16   25   54   68   0.871
                                 Presence                       96                    42                             3    7    17   27                                         Presence        19    9     2    2    3    4    
  Lymph vessel invasion          Absence                        140                   65                             8    12   21   34   0.296     Chemotherapy                No              160   78    10   14   21   37   0.061
                                 Presence                       162                   62                             11   13   38   38                                         Yes             142   51    8    12   36   35   

*M, month; LN, lymph node metastasis; LNR, lymph node ratio; TNM, tumor--node--metastasis; PI, prognostic index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus; PDAC, pancreatic ductal adenocarcinoma*.

![Post progression survival **(A)** and overall survival **(B)** stratified by time period to tumor progression diagnosis counted from the date of surgery.](fonc-09-01197-g0001){#F1}

Patterns of Recurrence
----------------------

Overall, there were six different patterns of recurrence for all radiological or pathological evidence of progression. Most of patients first recurred at the liver (*n* = 69, 39.9%), followed by local progression (*n* = 55, 31.8%), and lung metastases (*n* = 17, 9.8%). There were 20 (11.6%) patients who had both local and distant progression, and multiple recurrences were observed in 12 (6.9%) patients as the first progression. Liver and lung metastases were the most common distant metastases, compared with the local recurrence, and also contributed to most of the multiple progressions. The proportions of recurrence locations differed significantly at progressive time points. Distribution of these recurrent patterns is shown in [Figure 2](#F2){ref-type="fig"}. Liver-only progressions occupied the majority of all progressions within 6 months, whereas they were responsible for just 12.5% of all recurrences after 24 months since surgery (*P* \< 0.001). Also, liver-only progression diminished over time, and recurrences of other sites became more and more common 1 year later since surgery.

![Distribution of tumor progression pattern at different time points.](fonc-09-01197-g0002){#F2}

Patients with different progression patterns had significantly different cumulative recurrence rates in different time periods after surgery ([Supplement Figure 1](#SM1){ref-type="supplementary-material"}). It was shown that cumulative rates of liver metastasis were significantly higher than those of local and other sites of progression, whereas the cumulative rates of liver, lung, and local plus distant and multiple metastases were comparable. The pairwise comparisons of OS ([Figure 3](#F3){ref-type="fig"}), PPS ([Supplement Figure 2](#SM1){ref-type="supplementary-material"}), and PFS ([Figure 4](#F4){ref-type="fig"}) for patients with different recurrence patterns were conducted. Median OS for patients with local recurrence (29.4 months, 95% CI 24.5--39.6) was significantly longer than that of patients with multiple progressions (17.5 months, 95% CI 11.2--19.5), whereas patients with other recurrence patterns of progression had similar OS rates. Similar results of survival comparisons were observed for PPS. In terms of PFS, patients with local (9.0 months, 95% CI 6.4--10.6) and other sites of progressions (12.7 months, 95% CI 9.1--28.7) had similar median survival, whereas they were both higher than those with other patterns of progressions.

![Pairwise comparison of overall survival for different tumor progression patterns. **(A)** Stratification of patients using different progression patterns of progression free, local, liver only, lung only, others, local and distant and multiple progressions. **(B--P)** Stratification of patients by comparing the following patterns of progression: local vs. liver only, local vs. lung only, local vs. others, local vs. local + distant, local vs. multiple, liver only vs. lung only, liver only vs. others, liver only vs. local + distant, liver only vs. multiple, lung only vs. others, lung only vs. local + distant, lung only vs. multiple, others vs. local + distant, others vs. multiple and local + distant vs. multiple.](fonc-09-01197-g0003){#F3}

![Pairwise comparison of progression-free survival for different tumor progression patterns. **(A)** Stratification of patients using different progression patterns of progression free, local, liver only, lung only, others, local and distant and multiple progressions. **(B--P)** Stratification of patients by comparing the following patterns of progression: local vs. liver only, local vs. lung only, local vs. others, local vs. local + distant, local vs. multiple, liver only vs. lung only, liver only vs. others, liver only vs. local + distant, liver only vs. multiple, lung only vs. others, lung only vs. local + distant, lung only vs. multiple, others vs. local + distant, others vs. multiple and local + distant vs. multiple.](fonc-09-01197-g0004){#F4}

Risk Factors for Different Patterns of Recurrence
-------------------------------------------------

Results of univariate and multivariate logistic regression models for local recurrence and liver-only metastasis are shown in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, respectively. Also, risk factors of lung only, other sites of metastasis, local + distant, and multiple metastases are shown in [Supplement Tables 1--4](#SM2){ref-type="supplementary-material"}, respectively. Age older than 60 years was a strong predictor for both liver-only metastasis (hazard ratio \[HR\] = 1.35, 95% CI 1.21--1.73, *P* = 0.031) and multiple metastases (HR = 9.82, 95% CI 1.20--80.66, *P* = 0.033). Specific stations of LN metastases were significantly associated with different patterns of progressions, including LN15 metastasis as a predictor for liver-only (HR = 6.39, 95% CI 1.29--31.52, *P* = 0.023) and local + distant metastases (HR = 8.51, 95% CI 1.27--59.11, *P* = 0.030), LN18 metastasis as a predictor for local progression (HR = 8.97, 95% CI 1.48--54.23, *P* = 0.017), LN10 metastasis as a predictor for lung-only metastasis (HR = 15.96, 95% CI 1.89--134.86, *P* = 0.011), and LN14 metastasis as a predictor for multiple metastases (HR = 7.38, 95% CI 1.61--33.74, *P* = 0.010). Patients receiving adjuvant chemotherapy had a decreased likelihood of local progression (HR = 0.18, 95% CI 0.08--0.42, *P* \< 0.001) and lung-only metastasis (HR = 0.14, 95% CI 0.02--0.83, *P* = 0.031) than are those who did not receive adjuvant chemotherapy. Also, PLR was the only independent predictor for other sites of metastases (HR = 0.13, 95% CI 0.02--0.87, *P* = 0.036), and enlarged imaging LN size was found to increase the likelihood of local + distant metastases (HR = 4.57, 95% CI 1.34--15.60, *P* = 0.015).

###### 

Risk factors for local recurrence in PDAC patients after surgery.

  **Characteristics**            **Univariate analysis**   **Multivariate analysis**   **Characteristics**   **Univariate analysis**   **Multivariate analysis**                                                                                                                                           
  ------------------------------ ------------------------- --------------------------- --------------------- ------------------------- --------------------------- ------------- --------------------------- ------------------------- ----------- ------------ ------------ --------- ------ ------------ --
  Age                            ≤60 years                 Reference                   0.951                                                                       NI            Perineural invasion         Absence                   Reference   0.188                               NI                  
                                 \>60 years                1.02                        0.52--2.01                                                                                                                                      Presence    1.59         0.80--3.16                                 
  Gender                         Female                    Reference                   0.897                                                                                     Adjacent organ invasion     Absence                   Reference   0.941                               NI                  
                                 Male                      1.05                        0.52--2.09                                                                                                                                      Presence    0.96         0.32--2.90                                 
  LN metastasis                  Absence                   Reference                   0.060                                                                       NI            LNR                         0                         Reference                                       NI                  
                                 Presence                  1.92                        0.97--3.28                                                                                                                                      0--0.16     1.36         0.91--2.04   0.135                         
  LN5 metastasis                 Absence                   Reference                                                                                               NI                                        \>0.16                    1.50        0.70--3.22   0.302                                      
                                 Presence                  --                                                                                                                                                Satellite foci            Absence     Reference    0.470                         NI           
  LN6 metastasis                 Absence                   Reference                                                                                               NI                                        Presence                  0.47        0.06--3.66                                              
                                 Presence                  --                                                                                                                                                Tumor site                Head        Reference    0.964                         NI           
  LN7 metastasis                 Absence                   Reference                   0.783                                                                       NI                                        Body and tail             0.98        0.41--2.35                                              
                                 Presence                  1.36                        0.15--11.94                                                                                                           Imaging tumor size (cm)   ≤2          Reference                                  NI           
  LN8 metastasis                 Absence                   Reference                                                                                               NI                                        2--4                      1.74        0.79--3.85   0.173                                      
                                 Presence                  --                                                                                                                                                                          \>4         1.32         0.48--3.67   0.600                         
  LN9 metastasis                 Absence                   Reference                                                                                               NI            Imaging LN metastasis       Absence                   Reference   0.213                               NI                  
                                 Presence                  --                                                                                                                                                                          Presence    1.54         0.78--3.01                                 
  LN10 metastasis                Absence                   Reference                   0.913                                                                       NI            Imaging vascular invasion   Absence                   Reference   0.203                               NI                  
                                 Presence                  1.13                        0.13--9.62                                                                                                                                      Presence    1.62         0.77--3.40                                 
  LN11 metastasis                Absence                   Reference                   0.315                                                                       NI            Imaging LN size (cm)        ≤0.5                      Reference                                       NI                  
                                 Presence                  2.32                        0.45--11.90                                                                                                                                     0.5--1      0.63         0.23--1.75   0.374                         
  LN12 metastasis                Absence                   Reference                   0.163                                                                       NI                                        \>1                       2.01        0.94--4.32   0.073                                      
                                 Presence                  1.91                        0.77--4.75                                                                                                            PI                        0           Reference                                  NI           
  LN13 metastasis                Absence                   Reference                   0.460                                                                       NI                                        1                         0.94        0.43--2.06   0.878                                      
                                 Presence                  1.33                        0.63--2.83                                                                                                                                      2           1.86         0.57--6.04   0.304                         
  LN14 metastasis                Absence                   Reference                   0.389                                                                       NI            NLR                         ≤3.32                     Reference   0.203                               NI                  
                                 Presence                  1.65                        0.53--5.29                                                                                                                                      \>3.32      0.61         0.29--1.31                                 
  LN15 metastasis                Absence                   Reference                                                                                               NI            dNLR                        ≤3.32                     Reference   0.067                               NI                  
                                 Presence                  --                                                                                                                                                                          \>3.32      0.53         0.27--1.05                                 
  LN16 metastasis                Absence                   Reference                   0.814                                                                       NI            PLR                         ≤98.13                    Reference   0.731                               NI                  
                                 Presence                  0.83                        0.18--3.78                                                                                                                                      \>98.13     1.21         0.40--3.64                                 
  LN17 metastasis                Absence                   Reference                   0.870                                                                       NI            PNI                         0                         Reference   0.076                               NI                  
                                 Presence                  0.84                        0.10--6.90                                                                                                                                      1           2.64         0.90--7.73                                 
  LN18 metastasis                Absence                   Reference                   0.018                 Reference                 0.017                       SII           ≤1,000                      Reference                 0.110                                 NI                            
                                 Presence                  7.22                        1.40--37.15                                     8.97                        1.48--54.23                                                         \>1,000     0.51         0.23--1.16                                 
  Positive LN number             0                         Reference                                                                                               NI            mGPS                        0                         Reference                                       NI                  
                                 1--3                      1.72                        0.82--3.63            0.154                                                                                                                     1           0.92         0.39--2.14   0.843                         
                                 \>3                       1.82                        0.66--5.06            0.250                                                                                                                     2           1.21         0.43--3.41   0.720                         
  Pancreatic membrane invasion   Absence                   Reference                   0.432                                                                       NI            WBC count                   ≤10                       Reference   0.162                               NI                  
                                 Presence                  0.75                        0.37--1.53                                                                                                                                      \>10        2.13         0.74--6.14                                 
  Tumor size (cm)                ≤2                        Reference                                                                                               NI            ALB (g/L)                   ≤35                       Reference   0.977                               NI                  
                                 2--4                      1.17                        0.52--2.64            0.711                                                                                                                     \>35        0.99         0.39--2.51                                 
                                 \>4                       1.35                        0.53--3.44            0.537                                                                                           CRP (ng/L)                ≤3          Reference    0.975                         NI           
  Tumor differentiation          Well                      Reference                                                                                               NI                                        \>3                       1.01        0.50--2.07                                              
                                 Moderate                  1.21                        0.54--2.53            0.542                                                                                           CA19-9 (U/ml)             ≤35         Reference    0.485                         NI           
                                 Poor                      1.46                        0.76--3.68            0.286                                                                                                                     \>35        1.39         0.55--3.49                                 
  Macrovascular invasion         Absence                   Reference                   0.882                                                                       NI            CEA (ng/ml)                 ≤5                        Reference   0.204                               NI                  
                                 Presence                  1.09                        0.36--3.31                                                                                                                                      \>5         1.56         0.78--3.12                                 
  Microvascular invasion         Absence                   Reference                   0.555                                                                       NI            HBV infection               Absence                   Reference   0.288                               NI                  
                                 Presence                  1.24                        0.61--2.50                                                                                                                                      Presence    1.87         0.59--5.97                                 
  Lymph vessel invasion          Absence                   Reference                   0.462                                                                       NI            Chemotherapy                No                        Reference   0.001        Reference    \<0.001                       
                                 Presence                  1.21                        0.59--2.74                                                                                                                                      Yes         0.19         0.08--0.43             0.18   0.08--0.42   

*PDAC, pancreatic ductal adenocarcinoma; HR, hazard ratio; LNR, lymph node ratio; LN, lymph node metastasis; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus*.

###### 

Risk factors for liver metastases in PDAC patients after surgery.

  **Characteristics**            **Univariate analysis**   **Multivariate analysis**   **Characteristics**   **Univariate analysis**   **Multivariate analysis**                                                                                                                                                 
  ------------------------------ ------------------------- --------------------------- --------------------- ------------------------- --------------------------- --------------------- --------------------------- ------------------------- ----------- ------------ ------------ ------- ------ ------------ --
  Age                            ≤60 years                 Reference                   0.030                 Reference                 0.031                       Perineural invasion   Absence                     Reference                 0.145                                 NI                          
                                 \>60 years                1.32                        1.11--2.23                                      1.35                        1.21--1.73                                                                  Presence    1.59         0.85--2.97                               
  Gender                         Female                    Reference                   0.922                                                                       NI                    Adjacent organ invasion     Absence                   Reference   0.160                             NI                  
                                 Male                      1.03                        0.55--1.93                                                                                                                                              Presence    1.86         0.78--4.43                               
  LN metastasis                  Absence                   Reference                   0.901                                                                       NI                    LNR                         0                         Reference                                     NI                  
                                 Presence                  1.04                        0.56--1.93                                                                                                                                              0--0.16     1.311        0.90--1.92   0.165                       
  LN5 metastasis                 Absence                   Reference                                                                                               NI                                                \>0.16                    1.37        0.66--2.84   0.402                                    
                                 Presence                  --                                                                                                                                                        Satellite foci            Absence     Reference    0.076                       NI           
  LN6 metastasis                 Absence                   Reference                   0.636                                                                       NI                                                Presence                  2.76        0.90--8.47                                            
                                 Presence                  1.74                        0.18--17.04                                                                                                                   Tumor site                Head        Reference    0.614                       NI           
  LN7 metastasis                 Absence                   Reference                   0.269                                                                       NI                                                Body and tail             1.22        0.57--2.62                                            
                                 Presence                  2.65                        0.47--14.88                                                                                                                   Imaging tumor size (cm)   ≤2          Reference                                NI           
  LN8 metastasis                 Absence                   Reference                   0.500                                                                       NI                                                2--4                      1.28        0.64--2.57   0.489                                    
                                 Presence                  1.75                        0.34--8.95                                                                                                                                              \>4         1.11         0.45--2.73   0.816                       
  LN9 metastasis                 Absence                   Reference                   0.743                                                                       NI                    Imaging LN metastasis       Absence                   Reference   0.901                             NI                  
                                 Presence                  1.30                        0.27--6.33                                                                                                                                              Presence    1.04         0.56--1.93                               
  LN10 metastasis                Absence                   Reference                                                                                               NI                    Imaging vascular invasion   Absence                   Reference   0.031                     0.053                       
                                 Presence                  --                                                                                                                                                                                  Presence    2.07         1.07--4.03           2.08   0.99--4.38   
  LN11 metastasis                Absence                   Reference                   0.773                                                                       NI                    Imaging LN size (cm)        ≤0.5                      Reference                                     NI                  
                                 Presence                  0.73                        0.09--6.09                                                                                                                                              0.5--1      0.67         0.29--1.55   0.353                       
  LN12 metastasis                Absence                   Reference                   0.466                                                                       NI                                                \>1                       0.92        0.42--2.02   0.842                                    
                                 Presence                  1.40                        0.57--3.41                                                                                                                    PI                        0           Reference                                NI           
  LN13 metastasis                Absence                   Reference                   0.363                                                                       NI                                                1                         1.27        0.64--2.52   0.487                                    
                                 Presence                  1.38                        0.69--2.73                                                                                                                                              2           2.09         0.70--6.25   0.186                       
  LN14 metastasis                Absence                   Reference                   0.803                                                                       NI                    NLR                         ≤3.32                     Reference   0.106                             NI                  
                                 Presence                  0.85                        0.24--3.01                                                                                                                                              \>3.32      1.67         0.90--3.11                               
  LN15 metastasis                Absence                   Reference                   0.018                 Reference                 0.023                       dNLR                  ≤3.32                       Reference                 0.087                                 NI                          
                                 Presence                  5.53                        1.34--22.93                                     6.39                        1.29--31.52                                                                 \>3.32      1.88         0.91--3.85                               
  LN16 metastasis                Absence                   Reference                   0.050                 Reference                 0.252                       PLR                   ≤98.13                      Reference                 0.379                                 NI                          
                                 Presence                  2.80                        1.00--7.87                                      1.99                        0.61--6.49                                                                  \>98.13     1.63         0.55--4.83                               
  LN17 metastasis                Absence                   Reference                   0.623                                                                       NI                    PNI                         0                         Reference   0.836                             NI                  
                                 Presence                  1.50                        0.30--7.42                                                                                                                                              1           1.08         0.51--2.31                               
  LN18 metastasis                Absence                   Reference                                                                                               NI                    SII                         ≤1,000                    Reference   0.140                             NI                  
                                 Presence                  --                                                                                                                                                                                  \>1,000     1.61         0.86--3.02                               
  Positive LN number             0                         Reference                                                                                               NI                    mGPS                        0                         Reference                                     NI                  
                                 1--3                      1.53                        0.75--3.11            0.245                                                                                                                             1           1.38         0.67--2.83   0.380                       
                                 \>3                       2.15                        0.85--5.44            0.105                                                                                                                             2           1.27         0.49--3.35   0.623                       
  Pancreatic membrane invasion   Absence                   Reference                   0.063                                                                       NI                    WBC count                   ≤10                       Reference   0.152                             NI                  
                                 Presence                  1.79                        0.97--3.32                                                                                                                                              \>10        2.07         0.77--5.58                               
  Tumor size (cm)                ≤2                        Reference                                         Reference                                             ALB (g/L)             ≤35                         Reference                 0.840                                 NI                          
                                 2--4                      2.37                        1.03--5.47            0.043                     1.97                        0.83--4.68            0.124                                                 \>35        1.09         0.46--2.61                               
                                 \>4                       2.36                        0.92--6.08            0.074                     1.48                        0.53--4.19            0.457                       CRP (ng/L)                ≤3          Reference    0.359                       NI           
  Tumor differentiation          Well                      Reference                                                                                               NI                                                \>3                       1.35        0.72--2.53                                            
                                 Moderate                  0.11                        0.01--1.83            0.123                                                                                                   CA19-9 (U/ml)             ≤35         Reference    0.079                       NI           
                                 Poor                      0.29                        0.02--4.75            0.385                                                                                                                             \>35        2.39         0.90--6.32                               
  Macrovascular invasion         Absence                   Reference                   0.494                                                                       NI                    CEA (ng/ml)                 ≤5                        Reference   0.673                             NI                  
                                 Presence                  1.40                        0.54--3.63                                                                                                                                              \>5         1.15         0.60--2.19                               
  Microvascular invasion         Absence                   Reference                   0.633                                                                       NI                    HBV infection               Absence                   Reference   0.210                             NI                  
                                 Presence                  1.17                        0.61--2.23                                                                                                                                              Presence    0.27         0.04--2.09                               
  Lymph vessel invasion          Absence                   Reference                   0.287                                                                       NI                    Chemotherapy                No                        Reference   0.031        Reference    0.170                       
                                 Presence                  1.42                        0.58--1.67                                                                                                                                              Yes         0.50         0.27--0.94           0.63   0.32--1.22   

*PDAC, pancreatic ductal adenocarcinoma; HR, hazard ratio; LNR, lymph node ratio; LN, lymph node metastasis; PI, prognostic index; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus*.

Risk Factors for Progression-Free Survival and Overall Survival
---------------------------------------------------------------

For all included patients, 1-, 2-, and 3-year OS and PFS were 81.3, 58.4, and 47.0% and 49.7, 36.0, and 29.7%, respectively. In order to investigate the prognostic factors of survival, a total of 48 high-dimensional radiological and pathological data were incorporated in the LASSO regression ([Figure 5](#F5){ref-type="fig"}). Three best predictors for OS, including LN16 metastasis, tumor differentiation, and imaging tumor size, and another eight predictors for PFS, including the eighth edition tumor--node--metastasis (TNM) stage, liver-only metastasis, lung-only metastasis, local progression, multiple metastases, LN16 metastasis, imaging tumor size, and LNR, were identified. The predictors selected by LASSO regression, along with the associated clinical factors identified by a univariate analysis, were incorporated to the multivariable analysis. Subsequent analyses illustrated that decreased time interval to progression (HR = 4.30, 95% CI 2.57--7.20, *P* \< 0.001), elevated CA19-9 level (HR = 1.92, 95% CI 1.03--3.58, *P* = 0.039), and LN16 metastasis (HR = 3.63, 95% CI 1.68--7.82, *P* = 0.001) were independent predictors for reduced OS ([Table 4](#T4){ref-type="table"}). Independent prognostic factors for PFS included elevated CEA level (HR = 1.78, 95% CI 1.25--2.53, *P* = 0.002), local progression (HR = 8.84, 95% CI 5.25--14.87, *P* \< 0.001), liver-only metastasis (HR = 14.74, 95% CI 9.12--23.84, *P* \< 0.001), lung-only metastasis (HR = 9.41, 95% CI 4.45--19.91, *P* \< 0.001), local + distant progression (HR = 11.69, 95% CI 5.79--23.58, *P* \< 0.001), multiple metastases (HR = 19.51, 95% CI 8.78--43.38, *P* \< 0.001), LN16 metastasis (HR = 3.04, 95% CI 1.58--5.99, *P* \< 0.001), imaging tumor size (HR = 1.76, 95% CI 1.16--2.67, *P* = 0.008), chemotherapy (HR = 0.60, 95% CI 0.42--0.86, *P* = 0.005), and TNM stage (HR = 2.40, 95% CI 1.17--4.92, *P* = 0.017) ([Table 5](#T5){ref-type="table"}).

![Feature selection using the least absolute shrinkage and selection operator (LASSO) Cox regression model. LASSO coefficient profiles of 48 variables against the log (Lambda) sequence for PFS **(A)** and tuning parameter (Lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria for PFS **(B)**. LASSO coefficient profiles of 48 variables against the log (Lambda) sequence for OS **(C)** and tuning parameter (Lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria for OS **(D)**. PFS, progression-free survival; OS, overall survival.](fonc-09-01197-g0005){#F5}

###### 

Independent prognostic factors for OS.

  **Characteristics**                 **Univariate analysis**   **Multivariate analysis**                                                     
  ----------------------------------- ------------------------- --------------------------- ------------ ----------- ----------- ------------ ---------
  Age                                 ≤60 years                 Reference                                                        NI           
                                      \>60 years                1.40                        0.96--2.04   0.084                                
  Gender                              Female                    Reference                                                        NI           
                                      Male                      0.89                        0.61--1.31   0.556                                
  WBC count                           ≤10                       Reference                                Reference   0.234                    
                                      \>10                      2.43                        1.38--4.29   0.002       1.73        0.70--4.26   
  NLR                                 ≤3.32                     Reference                                                        NI           
                                      \>3.32                    1.16                        0.79--1.72   0.447                                
  dNLR                                ≤3.32                     Reference                                                        NI           
                                      \>3.32                    1.03                        0.69--1.54   0.903                                
  PLR                                 ≤98.13                    Reference                                                        NI           
                                      \>98.13                   1.16                        0.65--2.08   0.612                                
  PNI                                 0                         Reference                                                        NI           
                                      1                         1.30                        0.81--2.08   0.285                                
  SII                                 ≤1,000                    Reference                                                        NI           
                                      \>1,000                   0.93                        0.61--1.40   0.712                                
  mGPS                                0                         Reference                                                        NI           
                                      1                         1.40                        0.89--2.21   0.143                                
                                      2                         1.03                        0.58--1.83   0.927                                
  PI                                  0                         Reference                                                        NI           
                                      1                         1.20                        0.78--1.83   0.412                                
                                      2                         2.24                        1.18--4.26   0.014                                
  ALB (g/L)                           ≤35                       Reference                                                        NI           
                                      \>35                      0.97                        0.59--1.59   0.897                                
  CRP (ng/L)                          ≤3                        Reference                                                        NI           
                                      \>3                       1.24                        0.84--1.84   0.275                                
  CA19-9 (U/ml)                       ≤35                       Reference                                Reference   0.039                    
                                      \>35                      2.72                        1.52--4.87               1.92        1.03--3.58   
  CEA (ng/ml)                         ≤5                        Reference                                Reference   0.840                    
                                      \>5                       1.01                        1.00--1.02   0.019       1.05        0.68--1.61   
  HBV infection                       Absence                   Reference                                                        NI           
                                      Presence                  1.23                        0.54--2.81   0.624                                
  Chemotherapy                        No                        Reference                                                        NI           
                                      Yes                       0.81                        0.56--1.19   0.288                                
  Time period to recurrence (month)   ≤6                        Reference                                Reference                            
                                      6--12                     2.45                        1.34--3.57   \<0.001     2.67        1.52--4.69   \<0.001
                                      12--24                    3.33                        1.35--4.37   \<0.001     3.29        2.00--5.43   \<0.001
                                      \>24                      4.23                        2.34--6.45   \<0.001     4.30        2.57--7.20   \<0.001
  LN16 metastasis                     Absence                                                                        Reference                
                                      Presence                                                                       3.63        1.68--7.82   0.001
  Tumor differentiation               Well                                                                           Reference                
                                      Moderate                                                                       1.37        0.91--2.05   0.130
                                      Poor                                                                           1.45        0.87--2.98   0.13
  Imaging tumor size (cm)             ≤2                                                                             Reference                
                                      2--4                                                                           1.15        0.84--1.56   0.389
                                      \>4                                                                            1.34        0.76--1.78   0.267

*OS, overall survival; HR, hazard ratio; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; PI, prognostic index; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus*.

###### 

Independent prognostic factors for PFS.

  **Characteristics**          **Univariate analysis**   **Multivariate analysis**                                                      
  ---------------------------- ------------------------- --------------------------- ------------ ----------- ----------- ------------- -------
  Age                          ≤60 years                 Reference                                                        NI            
                               \>60 years                1.15                        0.85--1.55   0.365                                 
  Gender                       Female                    Reference                                                        NI            
                               Male                      1.15                        0.85--1.56   0.375                                 
  WBC count                    ≤10                       Reference                                Reference   0.052                     
                               \>10                      1.73                        1.05--2.85   0.032       1.74        0.99--3.05    
  NLR                          ≤3.32                     Reference                                                        NI            
                               \>3.32                    1.14                        0.84--1.56   0.390                                 
  dNLR                         ≤3.32                     Reference                                                        NI            
                               \>3.32                    0.94                        0.69--1.29   0.717                                 
  PLR                          ≤98.13                    Reference                                                        NI            
                               \>98.13                   1.32                        0.82--2.13   0.256                                 
  PNI                          0                         Reference                                                        NI            
                               1                         1.25                        0.86--1.82   0.244                                 
  SII                          ≤1,000                    Reference                                                        NI            
                               \>1,000                   0.96                        0.70--1.32   0.813                                 
  mGPS                         0                         Reference                                                        NI            
                               1                         1.34                        0.95--1.91   0.099                                 
                               2                         1.01                        0.62--1.62   0.987                                 
  PI                           0                         Reference                                                        NI            
                               1                         1.19                        0.85--1.66   0.298                                 
                               2                         1.68                        0.96--2.93   0.069                                 
  ALB (g/L)                    ≤35                       Reference                                                        NI            
                               \>35                      1.05                        0.69--1.58   0.825                                 
  CRP (ng/L)                   ≤3                        Reference                                                        NI            
                               \>3                       1.22                        0.89--1.66   0.216                                 
  CA19-9 (U/ml)                ≤35                       Reference                                Reference   0.997                     
                               \>35                      1.87                        1.22--2.86   0.004       0.99        0.62--1.62    
  CEA (ng/ml)                  ≤5                        Reference                                Reference   0.002                     
                               \>5                       1.60                        1.18--2.18   0.003       1.78        1.25--2.53    
  HBV infection                Absence                   Reference                                                        NI            
                               Presence                  0.98                        0.52--1.86   0.95                                  
  Chemotherapy                 No                        Reference                                Reference   0.005                     
                               Yes                       1.35                        1.00--1.82   0.050       0.60        0.42--0.86    
  Local recurrence             Absence                                                            Reference   \<0.001                   
                               Presence                                                                       8.84        5.25--14.87   
  Liver metastasis             Absence                                                            Reference   \<0.001                   
                               Presence                                                                       14.74       9.12--23.84   
  Lung metastasis              Absence                                                            Reference   \<0.001                   
                               Presence                                                                       9.41        4.45--19.91   
  Local + distant metastasis   Absence                                                            Reference   \<0.001                   
                               Presence                                                                       11.69       5.79--23.58   
  Multiple metastasis          Absence                                                            Reference   \<0.001                   
                               Presence                                                                       19.51       8.78--43.38   
  LN16 metastasis              Absence                                                            Reference   0.001                     
                               Presence                                                                       3.04        1.58--5.99    
  Imaging tumor size (cm)      ≤2                                                                             Reference                 
                               2--4                                                                           1.76        1.16--2.67    0.008
                               \>4                                                                            1.47        0.83--2.58    0.185
  LNR                          0                                                                              Reference                 
                               0--0.16                                                                        0.96        0.46--1.98    0.900
                               \>0.16                                                                         1.03        0.51--2.10    0.928
  TNM stage                    IA                                                                             Reference                 
                               IB                                                                             0.92        0.52--1.64    0.782
                               IIA                                                                            2.40        1.17--4.92    0.017
                               IIB                                                                            1.21        0.49--3.01    0.674
                               III                                                                            1.12        0.50--2.50    0.789
  Tumor differentiation        Well                                                                           Reference                 
                               Moderate                                                                       1.24        0.78--1.95    0.330
                               Poor                                                                           1.65        1.21--3.67    0.032

*PFS, progression-free survival; HR, hazard ratio; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; PI, prognostic index; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus; LNR, lymph node ratio; TNM, tumor--node--metastasis*.

Performance of Prediction for Overall Survival and Progression-Free Survival
----------------------------------------------------------------------------

The comparisons of ROC curves of the predictive systems on the basis of the risk factors and TNM stage system are shown in [Figure 6](#F6){ref-type="fig"}. The values of AUC for 1-, 2-, and 3-year OS and PFS prediction were 0.823, 0.844, and 0.858 and 0.789, 0.829, and 0.863, respectively, which were significant higher than those of the TNM stage system (OS, 1 year, 0.614; 2 years, 0.592; 3 years, 0.599; PFS, 1 year, 0.669; 2 years, 0.647; 3 years, 0.630). The predictive system also demonstrated significantly more valuable prediction performance with the C-indexes of 0.829 (95% CI 0.760--0.898) for OS and 0.797 (95% CI 0.723--0. 871) for PFS, respectively, than did the TNM stage system (C-index, OS, 0.588 \[95% CI 0.465--0.711\]; PFS, 0.619 \[95% CI 0.524--0.713\]).

![Comparisons of receiver operating characteristic (ROC) curves of both the predictive system and TNM stage system for predicting 1-, 2-, and 3-year OS **(A--C)** and PFS **(D--F)** for LAPC patients after surgery, respectively. TNM, tumor--node--metastasis; PFS, progression-free survival; OS, overall survival; LAPC, locally advanced pancreatic cancer.](fonc-09-01197-g0006){#F6}

Discussion {#s4}
==========

Pancreatic cancer has an extremely poor prognosis even after surgical resection. Recurrence was observed in more than 60% of all PDAC patients after surgery ([@B4], [@B16]) and remained the main reason of poor prognosis in these patients. In this study, recurrence was observed in 57.3% of patients. In addition, 68.2% of recurrences occurred at a distant site, illustrating that there were systemic diseases in these patients at the time of surgery. Also, 41.6% of recurrences occurred 2 years after surgery. Maybe recurrence-free survival for 2 years did not mean cure, and regular follow-up was also needed for these patients. Furthermore, it was shown that different time intervals or patterns of recurrence would both have different survival. These results suggested that maybe recurrence time interval and patterns were important aspects of recurrence, and the evaluation of factors associated with time intervals and patterns of recurrence opened the door to the exploration of unique biological behaviors of PDAC.

Although the prognostic value of recurrence in survival had been illustrated by previous studies, the current published results differed considerably. For instance, the recurrence rates of PDAC patients after surgery ranged from 38 to 88% in previous studies ([@B17]--[@B21]). The discrepancies might differ greatly owing to the variations of neoadjuvant treatment regimen and differences of time periods of follow-up. Additionally, the patterns and timing of recurrence of PDAC patients were also not clearly illustrated owing to small population size and limited period of follow-up ([@B22], [@B23]). Moreover, only "local," "distant," and "local + distant" groups were analyzed in most of these studies ([@B8], [@B9], [@B24]--[@B26]), and specific recurrence sites were seldom illustrated. In the present study, our detailed recurrence data allowed for further stratification of recurrence patterns in six separated groups: local, liver-only, lung-only, other, local + distant, and multiple metastases. Similar with those in other studies ([@B27], [@B28]), liver-only metastasis and local recurrence contributed to most of the disease progressions. Considering the time period to tumor progress, our study further illustrated that liver-only metastasis occurred mainly in early phase after surgery and diminished over time. Oppositely, other patterns of progressions, including local recurrence and lung metastasis, were more and more common along with time. Following the variations of progression patterns over time, patients might benefit from changes of therapy focus during the period of follow-up.

Progression patterns and time period were two important natural aspects of progression. Apart from the changes of progression patterns over time, it was shown that survival differences were significant when they were stratified by different sites of first recurrence and time periods to tumor progression. In the current study, liver-only metastasis led to the shortest median PFS of only 5.1 months, which was comparable with that of local + distant progression or multiple metastases. Owing to the high rates of occurrence, liver-only metastasis contributed to most of the local + distant progression and multiple metastases. This may partly explain the similar PFS among these three patterns of progression. Similar results were also observed in a study conducted by Suenaga et al. ([@B3]), which reported that the median PFS of PDAC patients after surgery was 6.0 months. Apart from liver-only and lung-only metastases, other sites of sole metastasis contributed the longest median PFS (median 12.7 months) among all patterns of progression, followed by local recurrence with a median PFS of 9.0 months. A similar result was also achieved in Vincent\'s study ([@B4]). Additionally, survival differences of OS and PPS were also explored in the present study. Compared with patients with liver-only metastasis, although patients with other sites of distant metastases had slightly short median PPS, they finally achieved longer median OS owing to the significantly extended PFS. Moreover, compared with other patterns of progression, local recurrence contributed to better OS, followed by other sites of sole metastasis, and better PPS, followed by lung-only metastasis. A complete understanding of why local recurrence and lung-only metastasis were associated with relatively favorable PPS remains elusive. A hypothesis assumed that the large capacity of tumor bed and lung allowed patients to endure a greater tumor burden, leading to extended survival ([@B29]). Considering the slow growth pattern and apparently less aggressive tumor biology of local progression and lung-only metastasis, maybe locally advanced pancreatic cancer (LAPC) patients can benefit from additional treatment of the subsequent lung and local recurrence after surgery. Additionally, the inherent nature of organ-specific metastasis might be explained by the distinct genetic signatures of both primary PDAC and metastatic lesions. The analysis of biological mechanisms would potentially provide personal therapeutic approaches.

The exploration of risk factors for organ-specific recurrences and predictive factors for survival formed another important finding of this study. Several characteristics were risk factors for liver-only metastasis, such as age older than 60 years and LN15 metastasis. Presence of specific stations of LN metastases could be interpreted as signs of increasing probabilities of progressions. LN18, LN15, and LN14 metastases were identified as predictors for local progression, local + distant metastases, and multiple metastases, respectively. Additionally, as an effective adjuvant therapy to increase survival, the effects of chemotherapy on patterns of progression were poorly understood. Similar with previous study ([@B4]), the current study showed that chemotherapy significantly reduced the likelihood of recurrence, especially for local recurrence and lung-only metastasis. Additionally, the prognostic factors were also explored. Apart from the conventional recurrence patterns, elevated levels of CEA, enlarged imaging tumor size, poor differentiation, and advanced TNM stages were all predictive factors of decreased PFS. The exact relation of poor differentiation and poor PFS remained unclear. Maybe this could be partly explained by the ability of PDAC to develop distant metastases, which could be enhanced by the molecules released by the poorly differentiated tumor, including epidermal growth factor, E-cadherin ([@B24]). On the other hand, an increasing time prior to tumor progression was also a predictive factor of improved OS, indicating more favorable tumor behavior in patients with late progression. After other risk factors were controlled, the multivariate analysis also illustrated that elevated level of CA19-9 and LN16 metastasis were significantly associated with decreased OS, suggesting that patients with these unfavorable characteristics needed to receive adjuvant therapy after surgery to earn prolonged survival. Similar with study conducted by Groot et al. ([@B30]), our results showed that chemotherapy was associated with less local progression and lung-only metastasis and was an independent predictor for PFS. However, the significant associations between chemotherapy and other patterns of recurrences were not observed, and chemotherapy failed to act as a predictor of OS in this study. Owing to the heterogeneity in the length and regimen of the chemotherapy, data on the adjuvant or neoadjuvant chemotherapy in the current literatures were often limited and contradictory. A previous study based on 1,375 patients did not show survival benefit from adjuvant chemotherapy ([@B31]), whereas in another study, the additional survival benefit from adjuvant chemotherapy was reported in PDAC patients ([@B32]). The selection bias partly contributed to this discrepancy in retrospective study, and maybe more insights concerning the survival benefit of chemotherapy were available from prospective studies.

It is important to note that the precise prediction of progression is essential for the individual treatment. An important advantage of this study was the use of a relatively large cohort to determine the risk factors for different patterns of recurrences and survival. Several independent prognostic factors were selected by evaluating high-dimensional radiological and clinicopathological variables in the current study. In addition, analyses of ROC curves and comparisons of the associated values of AUC and C-indexes of the predictive system and TNM stage system showed a strong predictive strength of the predictive system on the basis of risk factors for OS and PFS. The inclusion of additional clinicopathological variables guaranteed that the established predictive system was better in predicting OS and PFS than did the eighth edition of the TNM stage system. On the other hand, the different clinicopathological features of progression patterns and timing suggested that there might be unique biological features in different progressions. Currently, the molecular feature, *SMAD4*, was shown to have a close relationship with progression patterns. Tumors with *SMAD4* up-regulated tended to be localized, whereas the down-regulation or silence of this gene was likely to promote metastasis ([@B33]). Moreover, different regulation of specific genes was associated closely with different patterns of progressions in an animal model ([@B34], [@B35]). Therefore, maybe the combination of clinicopathological characteristics and genetic features would have more meaningful implications in predicting progressions. Clinicians could perform evaluation of recurrence risks and survival on the basis of individual risk factors of patients and specialize the adjuvant therapy, which fitted the current trend to personalized medicine.

This study has several limitations. First, the specific adjuvant therapies after surgery and the associated response to adjuvant therapy were unavailable. More detailed information of length and regimen of chemotherapy would further illustrate the association between therapy and progression. Second, this study only focused on the first recurrence, and subsequent progressions were not taken into accounted. Third, it was well-known that more progressions would be observed over time. In this study, the period of follow-up for all included patients was longer than 1 year, but this time period was not relatively long enough. Although patients were followed up with a median time of 2 years in this study, the whole view of progression in patients could be changed if patients were followed up even longer. A prospective study with an even longer period of follow-up is also needed to validate results of this study. Last, sometimes diagnoses of progression on the basis of imaging were challenging, and it was possible to overestimate the probabilities of progression in PDAC patients after surgery.

In conclusion, for PDAC patients after radical operation, the different patterns and timing of recurrence were accurately described in the present study. This study further identified the risk factors of different recurrence patterns, which could help to predict the occurrence of first tumor progression. Furthermore, individual predictors of OS and PFS were also identified and validated for these patients. These findings further suggested the linkages between different progression patterns and biological heterogeneity, and the exploration might provide new versions into the prediction of tumor progression, prognosis stratification, and a more personalized management for PDAC patients after surgery.
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